Protective effects of Ginkgo biloba supplementation on clinical outcomes in metabolic dysfunction-associated steatotic liver disease DOI Creative Commons
Tom Ryu, Beom Sun Chung, Jae Jun Lee

и другие.

Phytomedicine, Год журнала: 2025, Номер 143, С. 156889 - 156889

Опубликована: Май 21, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global health concern linked to increased risks of cardiovascular disease, chronic kidney (CKD), and premature mortality. Ginkgo biloba has shown potential therapeutic benefits in conditions characterized by metabolic dysfunction. This study aimed evaluate the protective effects supplementation on overall survival (OS) incidence renal outcomes specifically MASLD patients. cohort included 402,476 participants from UK Biobank, categorized into No (SLD) cohorts. users non-users were compared using inverse probability treatment weighting balance baseline characteristics. Clinical assessed Cox proportional hazards models, with subgroup analyses. was associated significantly improved OS [hazard ratio (HR) = 0.79, 95 % confidence interval (CI): 0.64-0.98, p 0.034) reduced events (HR 0.82, CI: 0.66-1.00, 0.012) CKD 0.73, 0.56-0.96, cohort, while no significant observed SLD cohort. Subgroup analyses indicated enhanced older adults, males, individuals BMI ≥ 25 kg/m², diabetic The beneficial pronounced patients advanced fibrosis. patients, particularly high-risk subgroups. These findings highlight as an adjunctive therapy management. first large-scale examine impact clinical MASLD, fibrosis-stratified providing insights its differential across severity.

Язык: Английский

Implementation of a WeChat mini-program-driven lifestyle intervention among overweight or obese individuals with metabolic dysfunction-associated fatty liver disease (Preprint) DOI
C. N. Sun, Guangyu Chen,

Cuicui Shi

и другие.

Опубликована: Апрель 18, 2025

BACKGROUND Weight loss is the standard recommendation for patients with metabolic dysfunction-associated fatty liver disease (MAFLD), but its successful implementation difficult in practice. Digital lifestyle interventions may provide an efficient and scalable solution to enhance patient self-management. OBJECTIVE This study aimed assess effects of a WeChat mini-program-delivered intervention on weight hepatic steatosis among overweight or obese individuals MAFLD METHODS Overweight adults clinically diagnosed transient elastography examination were enrolled this prospective randomized controlled trial. Patients randomly assigned receive either mini-program management (intervention group) care (control at 1:1 ratio. Body clinical parameters assessed baseline then 6 months. RESULTS Among 89 included patients, 60.0% achieved ≥5% loss, 24.4% had ≥10% group, which greater than those control group (P <0.05). Importantly, receiving significantly more likely achieve attenuation parameter （CAP）reduction CAP normalization (57.8% vs. 31.8%, P In parallel, presented reductions enzymes (ALT, AST, GGT) (fasting insulin, HbA1c, TG, HDL-C) According fibrosis assessment, only FibroScan-aspartate aminotransferase (FAST) score decreased No significant difference was found stiffness measurement (LSM) values noninvasive scores (APRI, FIB-4, NFS, Agile 3+) between groups (P>0.05). CONCLUSIONS coaching via demonstrates efficacy enhancing reduction, improving steatosis, ameliorating disorders, offering novel perspectives regarding practicality therapeutic value digital tools managing through behavioral interventions. CLINICALTRIAL Chinese Clinical Trial Registry ChiCTR2500100197; https://www.chictr.org.cn/

Язык: Английский

Процитировано

0
Influence of molecular form of eicosapentaenoic acid (EPA) on its in vitro digestion and in vivo pharmacokinetics: Monoacylglycerol, triacylglycerol, and ethyl ester forms DOI
Min‐Jie Cao, Fangwei Yang, David Julian McClements

и другие.

Food Bioscience, Год журнала: 2025, Номер 68, С. 106756 - 106756

Опубликована: Май 5, 2025

Язык: Английский

Процитировано

0
TREM2-expressing macrophages in liver diseases DOI
Xiaochen Wang, Zhiyong Qiu, Zhenyu Zhong

и другие.

Trends in Endocrinology and Metabolism, Год журнала: 2025, Номер unknown

Опубликована: Май 1, 2025

Язык: Английский

Процитировано

0
Protective effects of Ginkgo biloba supplementation on clinical outcomes in metabolic dysfunction-associated steatotic liver disease DOI Creative Commons
Tom Ryu, Beom Sun Chung, Jae Jun Lee

и другие.

Phytomedicine, Год журнала: 2025, Номер 143, С. 156889 - 156889

Опубликована: Май 21, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global health concern linked to increased risks of cardiovascular disease, chronic kidney (CKD), and premature mortality. Ginkgo biloba has shown potential therapeutic benefits in conditions characterized by metabolic dysfunction. This study aimed evaluate the protective effects supplementation on overall survival (OS) incidence renal outcomes specifically MASLD patients. cohort included 402,476 participants from UK Biobank, categorized into No (SLD) cohorts. users non-users were compared using inverse probability treatment weighting balance baseline characteristics. Clinical assessed Cox proportional hazards models, with subgroup analyses. was associated significantly improved OS [hazard ratio (HR) = 0.79, 95 % confidence interval (CI): 0.64-0.98, p 0.034) reduced events (HR 0.82, CI: 0.66-1.00, 0.012) CKD 0.73, 0.56-0.96, cohort, while no significant observed SLD cohort. Subgroup analyses indicated enhanced older adults, males, individuals BMI ≥ 25 kg/m², diabetic The beneficial pronounced patients advanced fibrosis. patients, particularly high-risk subgroups. These findings highlight as an adjunctive therapy management. first large-scale examine impact clinical MASLD, fibrosis-stratified providing insights its differential across severity.

Язык: Английский

Процитировано

0